AFP and hepatocellular carcinoma: However, it is important to note that despite one of the studies concluding that AFP provided no additional benefit to US in HCC surveillance [12], current data show that with the addition of semiannual serum AFP, as recommended in current surveillance guidelines, semi-annual US surveillance has similar performance to annual CT for the detection of early HCC in a surveillance population [14].